EG278167 Inhibitors
Mageb6b1, a member of the MAGE family, functions as a negative regulator of transcription by RNA polymerase II, operating within the nucleus. The predicted involvement in transcriptional regulation positions Mageb6b1 as a critical player in gene expression dynamics. The protein's activity is intricately linked to various cellular processes, and understanding its inhibition requires exploring the diverse pathways influenced by different classes of chemical inhibitors. Inhibition of Mageb6b1 involves targeting key cellular processes related to transcription and DNA dynamics. Direct inhibitors like Actinomycin D and Actinomycin C interfere with RNA polymerase II, directly disrupting the transcriptional machinery and hindering Mageb6b1's negative regulatory function. Indirect inhibitors, such as Flavopiridol and Triptolide, modulate cell cycle and transcriptional processes, respectively, showcasing the intricate interplay between cellular dynamics and Mageb6b1 function. Epigenetic regulators like Trichostatin A and Valproic Acid influence chromatin accessibility, emphasizing the role of epigenetic modifications in Mageb6b1 regulation.
Nucleotide metabolism inhibitors, like 5-Fluorouracil and 6-Mercaptopurine, indirectly impact Mageb6b1 by altering DNA synthesis and nucleotide pool availability. DNA-modifying agents such as Cisplatin and Mitomycin C induce DNA damage, indirectly influencing Mageb6b1 by disrupting the transcriptional machinery and DNA topology dynamics. The comprehensive overview of these inhibitors underscores the complexity of cellular pathways governing Mageb6b1 expression, providing valuable insights into potential strategies for modulating its transcriptional regulatory functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
DNA transcription inhibitor. Actinomycin D intercalates into DNA, hindering RNA polymerase II progression during transcription. This direct inhibition disrupts Mageb6b1's role in negative transcription regulation, unraveling the intricate connection between DNA transcription dynamics and gene regulation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
CDK inhibitor affecting cell cycle progression. Flavopiridol inhibits CDKs, indirectly impacting Mageb6b1 by altering the cell cycle dynamics. The connection between cell cycle regulation and Mageb6b1 expression highlights the interdependence of cellular processes in gene modulation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
HDAC inhibitor influencing histone acetylation. Trichostatin A disrupts histone deacetylation, indirectly impacting Mageb6b1 by altering chromatin accessibility. The link between epigenetic modifications and Mageb6b1 emphasizes the regulatory role of chromatin dynamics in gene expression modulation. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Thymidylate synthase inhibitor affecting DNA synthesis. 5-Fluorouracil disrupts nucleotide metabolism, indirectly influencing Mageb6b1 by altering DNA synthesis dynamics. The connection between DNA synthesis and Mageb6b1 highlights the impact of nucleotide availability on gene regulation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
DNA cross-linking agent affecting transcription. Cisplatin induces DNA damage, indirectly influencing Mageb6b1 by disrupting the transcriptional machinery. The connection between DNA damage response and Mageb6b1 underscores the intricate relationship between genomic integrity and gene regulation. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Transcriptional inhibitor affecting RNA polymerase II. Triptolide hinders RNA polymerase II, directly impacting transcription and disrupting Mageb6b1's negative transcriptional regulation. This emphasizes the critical role of transcriptional dynamics in governing Mageb6b1 expression and function. | ||||||
6-Mercaptopurine | 50-44-2 | sc-361087 sc-361087A | 50 mg 100 mg | $72.00 $104.00 | ||
Purine analog affecting nucleotide metabolism. 6-Mercaptopurine disrupts purine synthesis, indirectly influencing Mageb6b1 by altering nucleotide pool availability. The link between nucleotide metabolism and Mageb6b1 highlights the impact of cellular metabolic pathways on gene expression regulation. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Topoisomerase II inhibitor affecting DNA topology. Etoposide induces DNA breaks, indirectly impacting Mageb6b1 by altering DNA topology dynamics. The connection between DNA topology and Mageb6b1 emphasizes the regulatory role of genomic structure in modulating gene expression. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
HDAC inhibitor influencing histone acetylation. Valproic Acid disrupts histone deacetylation, indirectly impacting Mageb6b1 by altering chromatin accessibility. The link between epigenetic modifications and Mageb6b1 emphasizes the regulatory role of chromatin dynamics in gene expression modulation. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
DNA cross-linking agent affecting transcription. Mitomycin C induces DNA damage, indirectly influencing Mageb6b1 by disrupting the transcriptional machinery. The connection between DNA damage response and Mageb6b1 underscores the intricate relationship between genomic integrity and gene regulation. | ||||||